Compass pathways stock forecast.

17 de out. de 2022 ... Math over Myth is your weekly source for psychedelic stock updates, including Compass Pathways and Revive Therapeutics.

Compass pathways stock forecast. Things To Know About Compass pathways stock forecast.

Compass Pathways Stock Performance Analysis: August 4, 2023 On August 4, 2023, the stock performance of Compass Pathways (CMPS) was closely watched by investors and analysts. As per the data sourced from CNN Money, let’s delve into the key figures and analyze the implications for the company.Upgrade Your Account ... COMPASS Pathways plc NASDAQ: CMPS is a United Kingdom-based mental healthcare company developing psilocybin therapy through late-stage ...Learn More. Market Cap. (-2.86%) -$0.17. Current Price. The biotech is developing a treatment paradigm combining talk therapy with a purified version of psilocybin, the active ingredient in "magic ...Compass Pathways PLC. 5.94. Delayed Data. As of Nov 29. -0.04 / -0.67%. Today’s Change. 5.01. Today ||| 52-Week Range. 11.48.

Company's cash position stands at $248.0 million with a net loss of $33.4 million for Q3 2023. Get the latest COMPASS Pathways plc (CMPS) stock news and headlines to help you in your trading and ... Compass Pathways Plc. Market Cap. $399M. Today's Change. (6.61%) $0.40. Current Price. $6.45. Price as of November 24, 2023, 1:00 p.m. ET. You’re reading a free article with opinions that may ...Compass Pathways stock indicated to open around $25.00, or 47% above the $17 IPO price. Sep. 18, 2020 at 10:17 a.m. ET by Tomi Kilgore.

16 ส.ค. 2566 ... ... Price” requirement (as defined in the Nasdaq rules). COMPASS intends to use the net proceeds from the proposed financing to fund its pivotal ...CMPS - Compass Pathways Plc - ADR Stock - Stock Price, Institutional Ownership, Shareholders (NASDAQ)

Nov 13, 2023 · Future criteria checks 0/6. COMPASS Pathways's earnings are forecast to decline at 2.7% per annum while its annual revenue is expected to grow at 82.4% per year. EPS is expected to grow by 6.1% per annum. Return on equity is forecast to be -82.5% in 3 years. EF Hutton analyst Elemer Piros reiterated a Buy rating on COMPASS Pathways (CMPS – Research Report) today and set a price target of $38.00... EF Hutton analyst Elemer Piros reiterated a Buy rating on COMPASS Pathways (CMPS – Research ...Get the latest Compass Pathways PLC (CMPS) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and …Compass Pathways plc is followed by the analysts listed. Please note that any opinions, estimates or forecasts regarding Compass Pathways plc's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Compass Pathways plc or its management.

COMPASS Pathways Stock Price, News & Analysis (NASDAQ:CMPS) $5.98 +0.05 (+0.84%) (As of 04:00 PM ET) Compare Today's Range $5.91 $6.56 50-Day Range $5.27 $7.96 52-Week Range $5.01 $11.48 Volume 900,582 shs Average Volume 342,967 shs Market Capitalization $370.16 million P/E Ratio N/A Dividend Yield N/A Price Target $46.83

A high-level overview of COMPASS Pathways plc (CMPS) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.

Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies, and are pioneering the development of a ...CMPS Earnings Date and Information. COMPASS Pathways last posted its quarterly earnings data on November 2nd, 2023. The reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by $0.17. COMPASS Pathways has generated ($2.59) earnings per share over the last year ( ($2.59) diluted …WebCMPS - Compass Pathways Plc - ADR Stock - Stock Price, Institutional Ownership, Shareholders (NASDAQ)Compass Pathways : ... However, the expert forecasts the stock moving up to $25, implying 252% upside potential. If so, FAT would easily be one of the sin stocks to buy.2 พ.ย. 2566 ... Each share of common stock and accompanying common warrant to purchase one share of common stock are being sold at a combined price to the ...Stock Price Forecast. The 5 analysts offering 12-month price forecasts for Compass Pathways PLC have a median target of 38.00, with a high estimate of 120.00 ...2 พ.ย. 2566 ... Stock FTCH logo. FTCH · Farfetch Will Not Announce Third Quarter 2023 ... price prior to the financing, and will be exercisable at the election ...

The COMPASS Pathways plc stock forecast for tomorrow is $ 5.02, which would represent a -4.68% loss compared to the current price. In the next week, the price of CMPS is expected to decrease by -2.62% and hit $ 5.13. As far as the long-term COMPASS Pathways plc stock forecast is concerned, here’s what our predictions are currently suggesting. Compass Pathways stock indicated to open around $25.00, or 47% above the $17 IPO price. Sep. 18, 2020 at 10:17 a.m. ET by Tomi Kilgore.Compass Pathways Plc. Market Cap. $399M. Today's Change. (6.61%) $0.40. Current Price. $6.45. Price as of November 24, 2023, 1:00 p.m. ET. You’re reading a free article with opinions that may ...WebNov 30, 2023 · Overview Financials Statistics Forecast Profile Chart Forecast Analyst Ratings COMPASS Pathways Stock Forecast All Analysts Top Analysts Stock Price Forecast According to 5 stock analysts, the average 12-month stock price forecast for CMPS stock stock is $49.6, which predicts an increase of 722.55%. The lowest target is $19 and the highest is $120. It may have a tough pill to swallow, but I'm still optimistic about psilocybin in general, and especially Cybin....CMPS At the time of publication, Tim Collins was long CYBN. Look how quickly we got bulled up. Let's check sentiment, the...Find the latest Alpha Lithium Corporation (APHLF) stock quote, history, news and other vital information to help you with your stock trading and investing.

Psychedelics biotech giant COMPASS Pathways (NASDAQ: CMPS) has entered into a securities purchase agreement for an initial $125 million and potential additional of $160 million, with a select ...

The financials. The average price target from the nine analysts following COMPASS pathways is $68 against a current price of $14.9, implying a 356% upside and a target market cap of $3 billion. I ...17 ต.ค. 2565 ... Math over Myth is your weekly source for psychedelic stock updates, including Compass Pathways and Revive Therapeutics.Stock analysis for Compass Pathways Plc (CMPS:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.COMPASS Pathways' (NASDAQ:CMPS) Phase 2b study of synthetic psilocybin COMP360 paired with psychological support for Treatment-Resistant ... COMPASS Pathways' (NASDAQ:CMPS) Phase 2b study of synthetic psilocybin COMP360 paired with...What happened. Compass Pathways ( CMPS 6.18%) saw its shares drop more than 22% on Tuesday. The biotech stock, which focuses on mental health treatment, closed at $43.06 on Monday, opened at $40. ...WebDiscover historical prices for CMPS stock on Yahoo Finance. View daily, weekly or monthly format back to when COMPASS Pathways plc stock was issued.

COMPASS Pathways PLC ADR analyst ratings, historical stock prices, earnings estimates & actuals. CMPS updated stock price target summary.

Track COMPASS Pathways (CMPS) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that it has entered into a securities purchase agreement with a select group of healthcare specialist investors for the private placement of (i) 16,076,750 …In the last 3 months, 5 analysts have offered 12-month price targets for Compass Pathways. The company has an average price target of $50.6 with a high of $120.00 and a low of $19.00. Below is a ...Based on short-term price targets offered by six analysts, the average price target for COMPASS Pathways PLC Sponsored ADR comes to $48.67. The forecasts range from a low of $19.00 to a high...Past 5 Years (per annum) N/A. N/A. N/A. N/A. See COMPASS Pathways plc (CMPS) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.WebCurrently 16 wall-street analysts regularly analyze the financials of Compass Pathways Plc on a frequent basis to provide recommendations along with target share price. 16 analysts offering 12-month price forecasts for Compass Pathways Plc (CMPS) have a share price target of $42.13.WebMay 26, 2023 · COMPASS Pathways is looking at the long-term effects of COMP360 in our phase 3 programme in treatment-resistant depression.” Manish Agrawal, MD, Chief Executive Officer, Sunstone Therapies, and the trial’s Principal Investigator, said: “This pioneering study is the first of its kind, conducted within a community hospital cancer center. Company Size. 116 Employees. Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in ...COMPASS Pathways is a mental healthcare company that specializes in psilocybin therapy. Read more to see my thoughts on CMPS stock and why it is a Hold. ... CMPS Stock Forecast.COMPASS Pathways (NASDAQ: CMPS) has seen its earnings outlook for FY2023 revised by Cantor Fitzgerald. The equities researchers at Cantor Fitzgerald have raised their EPS estimates, predicting that the company will now earn ($2.08) per share for the year, up from their previous forecast of ($2.24).According to 5 stock analysts, the average 12-month stock price forecast for CMPS stock stock is $49.6, which predicts an increase of 668.99%. The lowest target is $19 and the highest is $120. On average, analysts rate CMPS stock stock as a strong buy.The upgrade of COMPASS Pathways PLC Sponsored ADR to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move ...COMPASS Pathways Announces Up to $285 Million Private Placement Financing Joined by Leading Healthcare Investors. Transaction led by healthcare specialist investors, TCGX and Aisling Capital. Net ...Web

Compass Pathways plc is followed by the analysts listed. Please note that any opinions, estimates or forecasts regarding Compass Pathways plc's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Compass Pathways plc or its management.Overall, the consensus among analysts is that Compass Pathways has a promising future ahead. CMPS Stock Analysis: Fluctuating Prices and Negative Earnings Growth, but Positive Forecast for the Future. On May 11, 2023, CMPS stock opened at the same price as the previous close, which was 8.59. Throughout the day, the stock’s price fluctuated ...COMPASS Pathways Stock Price, News & Analysis (NASDAQ:CMPS) $5.98 +0.05 (+0.84%) (As of 04:00 PM ET) Compare Today's Range $5.91 $6.56 50-Day Range $5.27 $7.96 52-Week Range $5.01 $11.48 Volume 900,582 shs Average Volume 342,967 shs Market Capitalization $370.16 million P/E Ratio N/A Dividend Yield N/A Price Target $46.83 Instagram:https://instagram. ford giantwho owns modelo beerbest health insurance georgiavalue of jfk half dollars The upgrade of COMPASS Pathways PLC Sponsored ADR to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move ... review of forex.combest cryptocurrency day trading 21.61M. MSFT. 377.43. -0.11%. 9.38M. View today's Compass Pathways Plc stock price and latest CMPS news and analysis. Create real-time notifications to follow any changes … asian share market A high-level overview of COMPASS Pathways plc (CMPS) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.That's true for all of the existing public psychedelic biotechs engaged in drug development, including such industry leaders as Compass Pathways (CMPS-2.26%) and Atai Life Sciences (ATAI-1.51% ...